Health Care • Medical/Dental Instruments
$0.58 ▼ -0.01
(-1.15%)
MKT CAP: $17.3M • VOL: 17.5K
52W L $1 52W H $1
RVP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $38.3M | $33.0M | $43.6M |
| YoY Revenue Growth % | +15.8% | -24.2% | — |
| Gross Profit | $47.0K | -$1.0M | — |
| Gross Margin % | 0.1% | -3.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.2M | -$21.1M | -$11.5M |
| Operating Margin % | -55.3% | -63.9% | -26.4% |
| Net Income (GAAP) | -$12.6M | -$11.9M | -$7.0M |
| EBITDA (Normalized) | — | -$20.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.1M | -$11.6M | $2.8M |
| Capital Expenditures (CapEx) | — | $1.4M | — |
| Free Cash Flow (FCF) | -$7.1M | -$13.0M | $2.8M |
| FCF Margin % | -18.5% | -39.3% | 6.3% |
| Return on Invested Capital (ROIC %) | -23.3% | -19.9% | — |
| Cash & Short-Term Equivalents | $2.6M | $4.2M | — |
| Total Debt (Short + Long Term) | — | $900.0K | — |
| Total Stockholders' Equity | $74.4M | $87.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RVP.